News

Investors Taking Action Against Celsius Holdings, Inc. Possible Outcomes

Investors Taking Action Against Celsius Holdings, Inc. Possible Outcomes

Investors Taking Action Against Celsius Holdings, Inc.

In recent developments, Celsius Holdings, Inc. (NASDAQ: CELH) has found itself at the center of a class action lawsuit. Robbins LLP, a firm known for its dedication to shareholder rights, informs investors that they may have the chance to join this class action. The lawsuit pertains to concerns regarding misrepresentation of business prospects during a specified period.

Understanding the Class Action

This class action covers all purchases of Celsius Holdings, Inc. common stock made between February 29, 2024, and September 4, 2024. It’s crucial for investors who experienced significant losses during this timeframe to consider participating. Take action now to ensure your voice is heard in this matter.

The Allegations Behind the Lawsuit

Central to the class action are several allegations against Celsius Holdings, Inc. The complaint asserts that the company did not reveal essential information about its operations, particularly in relation to its partnership with Pepsi. Investors were reportedly misled about the sustainability of Celsius' inventory and sales expectations. Specifically, the lawsuit claims that Celsius oversold inventory to Pepsi beyond the actual demand.

Implications of the Allegations

As part of the allegations, it is stated that Celsius faced a challenge of declining sales, which could ultimately impact its financial outlook. Such claims suggest that when the reality of the company's situation became clear, shareholders were left vulnerable, leading to a drop in stock value. This drop has understandably raised concerns among investors who believe they were misled about the true state of the company.

Who Can Participate?

Those who purchased shares within the mentioned timeframe are urged to take action. If you believe you meet the criteria, you are encouraged to apply to serve as a lead plaintiff in the class action suit. This role involves acting on behalf of fellow shareholders in guiding the litigation process.

Next Steps for Investors

Investors interested in joining the class action have until January 21, 2025, to submit their applications. It is important to note that taking no action does not disqualify individuals from receiving a potential recovery. Therefore, understanding your rights and options as an investor is crucial at this juncture.

About Robbins LLP

Robbins LLP is a prominent law firm specializing in securities litigation. Since its establishment, it has successfully assisted shareholders in reclaiming losses and enhancing corporate governance. Their commitment to shareholder representation sets them apart in this field, making them a trusted ally for those impacted by corporate actions.

Keeping Updated

To stay informed about developments in this case or any related class actions, investors may sign up for alerts. Such notifications can provide timely updates, ensuring that shareholders are not left in the dark regarding their investments.

Frequently Asked Questions

What is the deadline for participation in the Celsius class action?

The deadline for investors to submit their applications to participate as lead plaintiffs is January 21, 2025.

Who can join the class action?

Investors who purchased Celsius Holdings, Inc. common stock between February 29, 2024, and September 4, 2024, are eligible to join.

What are the core allegations against Celsius Holdings?

The allegations include misleading investors about the sustainability of sales and inventory concerning their partnership with Pepsi.

What should I do if I am impacted?

If you have incurred significant losses, consider joining the class action and consulting with Robbins LLP for guidance.

How can I stay updated on the case?

You can sign up for alerts to receive notifications about any developments or settlements related to the class action against Celsius Holdings.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Hims & Hers Faces FTC Heat: Investor Class Action Looms

Updated Category News Views 0

Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...

Continue Reading
Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Updated Category News Views 206

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Continue Reading
Air Sealing First: Boosting Home Comfort & Efficiency

Updated Category News Views 0

Everyone wants a cozy, energy-efficient home, right? Well, the first step to achieving that might just surprise you. Forget about shoving more insulation into the walls for a second; air sealing should be your starting line. That's the drum Insulation Expert Mike Mancuso is beating, and he's got a point worth considering before you touch another insulation panel. Cracking...

Continue Reading
DigitalXForce Shakes Up GRC: AI-Infused X-ROC Launch

Updated Category News Views 64

Turning Risk Management on Its Head Well, here's a company not just tinkering around the edges but flipping the script on Governance, Risk, and Compliance (GRC) with their latest rollout: DigitalXForce and its X-ROC. Yeah, it's yet another acronym to juggle, but don't roll your eyes just yet. This AI-driven beast isn't about occasional boardroom reports. No sir, it's a...

Continue Reading
RYBREVANT's Promising Results in HNSCC Treatment

Updated Category News Views 50

Impressive Outcomes for RYBREVANT FASPRO in Head and Neck Cancer Tucked away in the endless cycle of drug trials, a glimmer of hope shines through with new data on RYBREVANT FASPRO in treating head and neck squamous cell carcinoma (HNSCC). This science talk might not rattle the ticker tape directly on NYSE:JNJ, but it has all the makings of a game-changer in the oncology...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 208

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Borr Drilling's Rig Sinks, Uncertainty Looms Offshore

Updated Category News Views 79

Unexpected Turn of Events at Sea Now here's a gut-punch nobody saw coming. Borr Drilling Limited (NYSE and OSE: BORR) got hit hard when their Prospector 5 drilling rig went under the waves offshore Gabon. This ain't no desk job dilemma; we're talking about a real-life offshore catastrophe. It all went down on October 24, 2026, when the rig experienced a punch through...

Continue Reading
DIRECTV Bags New NHL Deals: Stakes for Sports Fans

Updated Category News Views 287

NHL Fans, Strap in: DIRECTV Expands Its Lineup In a world where keeping up with your favorite team gets tougher each day, DIRECTV just lobbed a puck right into the net with their latest play. They've snagged a multi-year deal with the NHL for the Carolina Hurricanes, Columbus Blue Jackets, Minnesota Wild, and St. Louis Blues networks. It's a game changer, folks. If you...

Continue Reading
LexisNexis Debuts AI-Guided Field Clarity at IACP 2026

Updated Category News Views 7

LexisNexis Takes a Serious Step Forward The world of law enforcement reporting just got a shake-up. LexisNexis Coplogic Solutions launched a souped-up version of its Desk Officer Reporting System (DORS) at the IACP 2026 event. They paired DORS with Field Clarity, a newfangled AI-powered assistant that aims to make police reporting slicker and more accurate. You can bet...

Continue Reading
CapCut's Role in AI-Assisted Small Biz Marketing

Updated Category News Views 124

In today's fast-paced digital world, small businesses lament the constant hustle to stay relevant online. This juggling act with limited resources often makes effective marketing feel like a high-wire circus performance. Enter AI tools, promising to lighten the load, and CapCut stands out as a game-changer. AI Tools Revolutionizing Small Business Marketing Amid growing...

Continue Reading

Top 5 Most Recently Viewed Articles

Revolutionizing Elections: How EP3 Technology Transformed Voting

Updated Category News Views 114

EP3 Technology Powers Transformative Election Insights ForecastEx, a dynamic subsidiary of Interactive Brokers (IBKR), achieved a remarkable feat by processing over $560 million in election contracts during the 2024 U.S. general election. The groundbreaking technology enabling this achievement is Connamara Technologies' EP3 matching engine, an innovative platform designed...

Continue Reading
GI Partners and Legacy Investing Transform Chicago Landmark

Updated Category News Views 269

Transforming a Chicago Landmark into a Modern Data Center The historic 300,500 square foot building located at 400 S. LaSalle Street, once the home of the Chicago Board Options Exchange, is set to undergo an exciting transformation. Through an acquisition announced recently, GI Partners and Legacy Investing, LLC have acquired this prominent property with the intention of...

Continue Reading
Radiotherapy Market to Hit $10.68B in 2031, Growth Ahead

Updated Category News Views 30

Radiotherapy Market's Projected Growth: What's Fueling It? It's no secret: the radiotherapy market is on an upward trajectory, heading toward a substantial $10.68 billion valuation by 2031. But what’s pushing this rocket? For starters, we’re looking at a steady compound annual growth rate (CAGR) of 6.0% from 2026 to 2031. Not too shabby in today’s volatile economic...

Continue Reading
Join the Class Action Against Newmont Corporation by April 2025

Updated Category News Views 254

Take Action: Class Action Against Newmont Corporation Levi & Korsinsky, LLP is reaching out to investors linked to Newmont Corporation, urging them to act before the April 1, 2025 deadline for joining a class action lawsuit. This lawsuit addresses alleged securities fraud that negatively impacted many of Newmont's investors. Understanding the Class Action The class action...

Continue Reading
InflaRx Unveils Promising Preclinical Findings for INF904

Updated Category News Views 76

InflaRx Unveils New Developments for INF904 InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company recognized for its innovative anti-inflammatory therapies targeting the complement system, has recently shared promising preclinical results for its oral C5aR inhibitor, INF904. This announcement took place at the 2024 European Meeting on Complement in Human Diseases...

Continue Reading